Why the study?
Does long-term antithrombotic prophylaxis with rivaroxaban prevent clinical recurrence in a young patient with severe combined inherited thrombophilia?
Does long-term antithrombotic prophylaxis with rivaroxaban prevent clinical recurrence in a young patient with severe combined inherited thrombophilia?
Rivaroxaban may be an effective long-term antithrombotic prophylaxis for patients with exceptional combined inherited thrombophilia.
May support individualized long-term rivaroxaban in rare combined thrombophilias; leaves open optimal strategies for exceptional genotypes.
: We herein report the case of a young patient who presented with premature thromboembolic venous disease secondary to combined heterozygous G20210A prothrombin mutation, dual homozygosity for Factor V Leiden, and severe protein S deficiency. This association has never been reported to date and is likely to be exceptional, even in populations wherein these thrombophilia traits are more common. Long-term antithrombotic prophylaxis with rivaroxaban has proven successful in preventing clinical recurrence under prolonged treatment.
No takes yet. Share an insight, caveat, or question.
Krumb et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: